Answers are grounded in this paper and cite their sources.
Prescribing inertia and age discrimination in HFrEF management lead to suboptimal care in older patients, highlighting the need for aggressive adherence to guideline-directed therapies regardless of age.
This article refers to ‘Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata’ by D. Stolfo et al., published in this issue on pages 1047–1062. Earlier identification and better treatment of hypertension, hyperlipidaemia, type 2 diabetes, atrial fibrillation and myocardial infarction delay the onset of heart failure and death. However, the longer that death is delayed, the greater the risk of developing heart failure.1 Heart failure may be an almost inevitable consequence of survival into old age, although the diagnosis is usually missed until the problem is severe.2 In Europe, half or more of all patients with a new diagnosis of heart failure will be aged >75 years.3, 4 For those with heart failure and a reduced ejection fraction (HFrEF), mostly treated with loop diuretics for the control of symptoms and signs of congestion,2, 5 a series of landmark trials has found a therapeutic combination that reduces morbidity and mortality substantially6. Regrettably, in clinical practice, many patients are still treated sub-optimally, particularly if they are old.7 In this issue of the Journal, Stolfo and colleagues report that both the use and achieved doses of guideline-recommended therapies for HFrEF decline with age in a large nationwide sample of patients with HFrEF enrolled in Sweden between 2000 and 2018.7 Compared to younger patients, older patients with HFrEF were also less likely to receive cardiac resynchronization therapy (CRT) or an implantable cardioverter defibrillator (ICD). The absolute difference in pharmacological and device interventions was typically 10%–20% lower in patients aged ≥80 years compared to those aged <70 years. However, regardless of age, rates of prescribing renin–angiotensin system inhibitors and beta-blockers were excellent by international standards, although rates for mineralocorticoid receptor antagonists (MRAs) less so.3 In Sweden, the quality of care for most patients with heart failure exceeds that for many other countries. What might account for this apparent age discrimination in the management of HFrEF? It is important to realise that discrimination, when applied to therapeutic decisions, can be a force for good as well as for evil. First, we should ask if this registry is representative of clinical practice in Sweden. Only 27 430 patients with HFrEF were enrolled over 18 years from a population of about 10 million. Assuming an incidence of three cases of heart failure per thousand population per year1 with half of new cases being HFrEF, then 15 000 new cases of HFrEF per year would be expected in Sweden and about 300 000 new cases over the lifetime of the registry. It is likely that patients enrolled in the Swedish registry received more attention and better care than the majority of patients with HFrEF in Sweden.8 If prescribing inertia is not aggressively fought, many patients with HFrEF will continue to receive poor quality care. In a longitudinal analysis of a HFrEF registry in the USA, very few medication changes were made during a 1-year follow-up and most patients remained on sub-optimal doses.17 In an audit of an experienced heart failure clinic in the UK, missed opportunities for the uptitration of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers during a 12-month follow-up period were common and without an obvious explanation in half of cases.18 An analysis of consecutive follow-up appointments from the same service found that 50% of instances where treatment to lower heart rate should have been given, neither the dose of beta-blockers was increased nor ivabradine initiated.19 Fear of side effects and complaints, leading to prescribing inertia (primum non nocere), might get the best short-term results but will have dire long-term consequences. A frank and honest discussion around an ideal management plan with the patient, their family, and a multi-disciplinary health care team (enhanced by modern technology) is required. Fragmentation of care across specialities for patients with many comorbid conditions must be avoided as it is very confusing, depressing and de-motivating for both patients and staff. Electronic health records, ideally linked to a telemonitoring service, are an essential tool for care coordination across specialities and between primary and secondary care. Education, motivation and automated reminders are required for both patients and health care providers. Even if extending life is not the primary goal of treatment, polypharmacy is likely to be required for the foreseeable future for patients with HFrEF. Regular review of medications should be done and unnecessary treatments stopped, which will enhance adherence to effective medicines. For patients who have decided it is not yet time to withhold life-sustaining treatment, there are no grounds for complacency, regardless of their age. P.P. and J.G.F.C. are supported by the British Heart Foundation Centre of Research Excellence (RE/18/6134217).
No takes yet. Share an insight, caveat, or question.
Pellicori et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: